»
The US is resuming its rollout of Johnson & Johnson s vaccine after a pause to investigate blood clots
The US is resuming its rollout of Johnson & Johnson s vaccine after a pause to investigate blood clots
Andrew Dunn,Allison DeAngelis,Charles DavisApr 24, 2021, 06:02 IST
Nurse Elizabeth Johnson administers a COVID-19 vaccine to Melissa Mendez in Reading, Pennsylvania.Ben Hasty/MediaNews Group/Reading Eagle/Getty Images
The US will resume using Johnson & Johnson s coronavirus
vaccine.
CDC committee voted to recommend using the shots.
The US paused its rollout on April 13, citing concerns over rare blood clots.
The US will resume using Johnson & Johnson s
COVID-19 vaccine, more than a week after regulators paused the rollout to investigate reports of rare but serious side effects.
This week, our reporters also spent some time looking at the potential future of biotech.
Andrew Dunn pinpointed 5 takeaways from Walter Isaacson s best-selling book on Jennifer Doudna, the pioneering scientist who won a Nobel Prize for discovering CRISPR including what ethical questions now face the cutting-edge gene-editing tool.
Meanwhile, Patricia Kelly Yeo took a closer look at the plans Moderna s laid out to develop an HIV vaccine.
After the success of Moderna s COVID-19 vaccine, it s possible the biotech could chart a new path toward a vaccine that s eluded researches for decades.
Courtesy of Ariel Mary Ann; Facebook; Skye Gould/Insider
More trans people were killed in 2020 than in any year on record. A majority were Black trans women.
The American Medical Association said that while the rate of violence is increasing, we are nowhere near the breaking point.
Moderna s partnership will build on a new and unproven vaccine approach
William Schief, an immunology professor at Scripps Research and vaccine design director of the International AIDS Vaccine Initiative, presented Moderna s investors with unpublished data from an HIV vaccine trial presented at a virtual AIDS research conference in February.
The trial, which started in 2018, was conducted with 48 HIV-negative adults, and will serve as preliminary basis off which Moderna and its collaborators will further study and test a vaccine approach targeting broadly neutralizing antibodies. Subjects were given either a low or high dose of the protein-based vaccine candidate, which was designed to activate certain naive B cells of the immune system.